Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...
Telehealth company Hims & Hers' first Super Bowl ad is provocative and effective in building awareness of its weight loss ...
Novo Nordisk NVO is scheduled to report fourth-quarter 2024 results on Feb. 5, 2025, before the opening bell. The Zacks ...
The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go ...
NPA chairman Nick Kaye told the PA news agency that while obesity is "one of the biggest challenges facing" the UK, they are ...
Expanded Ozempic approval in the U.S. could transform how doctors treat patients with chronic kidney disease, which involves ...
Actress and comedian Amy Schumer said she took Ozempic three years ago and quickly lost 30 lbs. However, she quit the ...
24/7 Wall St. on MSN13d
Billionaire Sold Palantir and Is Buying This Stock That Could Soar 237%, According to a Wall Street ExpertPalantir Technologies (NASDAQ:PLTR) has been described as the best pure-play stock in artificial intelligence. The market ...
marketed as Ozempic pre-filled pen and Rybelsus oral tablet for T2D and as Wegovy injection for weight management. Wegovy is a significant contributor to Novo Nordisk's revenues. Despite supply ...
Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback